Key elements to successful translational drug development

  • Close collaboration between clinicians and basic scientists
  • Access to the top minds in the multiple myeloma field
  • Good communication of discoveries and advances in the field
  • High-quality multiple myeloma research samples and reagents
  • On-going training of the next generation of myeloma researchers and clinicians

The team at UCSF has built the Grand MMTI organization to facilitate successful translational drug development by:

  • Providing seed funding to UCSF researchers to foster pioneering research in multiple myeloma
  • Providing funding to support innovative multiple myeloma clinical trials
  • Providing funding to support training of clinical fellows in multiple myeloma
  • Meeting monthly to provide updates on programs and share ideas
  • Maintaining an expanding tissue bank and database that offers important samples to Grand MMTI researchers, as well as industry collaborators
  • Establishing a world class scientific advisory board composed of leading multiple myeloma experts
  • Fostering collaborations with other multiple myeloma groups to exploit synergies.

The research carried out by the Grand MMTI team is focused in a number of areas known to be important in multiple myeloma disease and treatment:

  1. Apoptotic pathways
  2. Unfolded Protein Response
  3. Kinase signaling pathways
  4. Ubiquitin proteasome system
  5. Biomarkers

As the Grand MMTI program grows, additional targets will be evaluated and, when appropriate, advanced as targets for novel therapeutic development.

Grant MMTI Organization